Galectin Therapeutics Inc.

GALT Healthcare Biotechnology

In the quarter to June 2026, EPS fell 16.7%, free cash flow grew 63.1% and total debt fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.62 0.09 −2.43%
Market cap
$374.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
17.72 15.12 25.66 18.59 39.65 27.14 47.48 8.25 3.05 15.36
Total current assets
19.44 17.25 27.71 20.55 41.82 29.47 48.21 8.83 3.82 15.79
Goodwill and Intangible Assets (Total)
— — — — — — — — — 0.00
Long-term assets (Other)
0.10 0.24 0.49 0.73 0.01 0.14 0.26 0.17 0.34 —
Total non-current assets
0.10 0.24 0.49 0.73 0.01 0.14 0.26 0.17 0.34 0.00
Total Assets
19.53 17.50 28.20 21.29 41.83 29.60 48.47 9.01 4.16 15.80
Notes Payable
— 21.12 — — — — — — — —
Accounts Payable
3.25 5.66 6.43 3.89 1.81 1.29 1.66 0.30 0.61 0.91
Dividends Payable
0.06 0.06 0.06 0.06 0.07 0.07 0.07 0.30 0.07 0.07
Accrued Expenses
4.72 8.20 9.18 9.06 7.16 4.04 1.09 1.51 2.29 2.80
Other current liabilities
— 0.37 — 9.08 7.22 4.06 1.12 1.81 2.36 3.78
Total current liabilities
8.03 35.41 15.68 13.01 9.03 5.40 2.82 2.11 2.97 3.78
Long Term Debt (Total)
133.74 85.11 71.74 39.83 29.05 0.01 0.05 — — —
Non-current Liabilities (Other)
3.96 0.05 1.02 0.64 1.13 0.01 0.05 — — —
Total non-current liabilities
137.70 85.16 72.77 40.47 30.18 0.01 0.05 — — —
Total liabilities
145.73 120.57 88.44 53.48 39.21 5.41 2.87 2.11 2.97 3.78
Additional Paid In Capital
304.07 296.22 291.85 275.08 271.00 261.88 259.67 194.13 173.36 166.72
Preferred Stock (Total)
2.21 2.22 2.22 2.23 2.25 2.25 2.26 8.94 8.96 8.96
Common Stock (Net)
0.07 0.06 0.06 0.06 0.06 0.06 0.06 0.04 0.04 0.03
Retained Earnings
(432.55) (401.57) (354.37) (309.57) (270.69) (240.00) (216.39) (196.21) (181.17) (163.70)
Common Equity (Total)
(128.41) (105.29) (62.46) (34.43) 0.37 21.94 43.34 (2.04) (7.77) 3.05
Shareholders Equity (Total)
(126.19) (103.07) (60.24) (32.19) 2.62 24.19 45.60 6.90 1.19 12.02
Shareholders Equity and Liabilities (Total)
19.53 17.50 28.20 21.29 41.83 29.60 48.47 9.01 4.16 15.80
Shares (Common)
65.20 63.16 61.85 59.43 59.34 57.08 56.89 41.19 35.79 32.91
Shares (Preferred)
1.21 1.24 1.24 1.26 1.30 1.30 1.33 6.84 6.89 6.89
Shareholders Equity (Tangible)
(126.19) (103.07) (60.24) (32.19) 2.62 24.19 45.60 6.90 1.19 12.01
Net Debt
116.02 69.99 46.08 21.24 (10.60) (27.13) (47.43) (8.25) (3.05) (15.36)
Total Debt
133.74 85.11 71.74 39.83 29.05 0.01 0.05 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates